Crawford joins lobbying firm
This article was originally published in The Tan Sheet
Former FDA Commissioner Lester Crawford joined the lobbying firm Policy Directions in January as senior counsel. The government relations firm counts the Pharmaceutical Research & Manufacturers of America, the Biotechnology Industry Organization and several major pharmaceutical companies as clients. According to public disclosures, PhRMA paid Policy Directions $120,000 in 2005 to lobby Congress, HHS and FDA on importation, FDA regulation and user fees. Additionally, Merck and Genzyme each paid the firm $80,000 in 2005. According to the firm's website, it was involved in modifying the Controlled Substances Act, it helped garner support for the "Best Pharmaceuticals for Children Act" and "successfully achieved FDA advisory committee support for a product that had originally been voted down." Crawford's abrupt departure from FDA has been under review by the HHS Inspector General (1"The Tan Sheet" Sept. 26, 2005, p. 5)...
You may also be interested in...
National Cancer Institute Director Andrew von Eschenbach, MD, brings extensive scientific expertise and experience working with Congress as the head of a high-profile federal agency to the role of FDA commissioner
United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.
The director of the agency’s patient focused drug development program talks to the Pink Sheet about how the program has improved the development and evaluation of new drugs, initiatives underway, and plans to standardize and harmonize the process.